Trenchant Bio is making cell and gene therapies (CGT) more affordable and accessible to patients.

We were founded in 2022 to create cell therapy manufacturing technologies and processes to be scalable, efficient, rapid, and affordable. Our singular focus is on solving the CGT manufacturing problem that is currently too lengthy, cumbersome, and unreliable. Our founding team has first-hand experience with the current CGT manufacturing process, and is developing technologies and process improvements to improve manufacturing.

Our Team

  • Philip Coelho, CHAIRMAN, CHIEF TECHNOLOGY OFFICER, FOUNDER

    Philip Coelho

    CHAIRMAN | CHIEF TECHNOLOGY OFFICER | FOUNDER

    Philip is a successful serial entrepreneur. As an engineer and inventor, Philip has over 50 US patents and 200 worldwide for technologies enabling the automated manufacturing of first generation (cord blood & bone marrow) and second-generation gene modified cell therapies. He successfully promoted the passage of the U.S. Stem Cell Therapeutic and Research Act of 2005. 

  • Jon Ellis, CHIEF EXECUTIVE OFFICER, FOUNDER

    Jon Ellis

    CHIEF EXECUTIVE OFFICER | FOUNDER

    Jon has collaborated with established cell therapy biotech and pharmaceutical companies to develop new processes, platform technologies and to improve manufacturing efficiency. He has developed and launched multiple cell therapy products. A cell biologist by training with over 20 years’ experience in different aspects of commercial cell therapy including research, product and process development, GMP manufacturing, clinical trials, business development and leadership.

  • William Busa, CO-FOUNDER

    William Busa

    CO-FOUNDER

    Following a first career in academia at The Johns Hopkins University studying signal transduction biology, Bill served as the founding Chief Scientific Officer of the biotech tools company, Cellomics, the originator of high content screening technology for pharmaceutical drug discovery. Bill next built and led a cell and tissue technologies product development organization at Becton Dickinson, and later became an independent business and product development consultant to the biotechnology tools industry.

  • Joel Bodenmann, CHIEF DEVELOPMENT OFFICER

    Joel Bodenmann

    CHIEF DEVELOPMENT OFFICER

    Joel has led the development of GMP manufacturing platforms. He has also created numerous proprietary platforms including μGFX, a flexible user interface used globally across multiple industries for mission critical systems. A systems engineer by training, he has developed control system architecture for multiple clients including Intel, Siemens, Audi, BMW and Logitech.